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Abstract
Introduction Human RAD51 is a homologue of the Escherichia
coli RecA protein and is known to function in recombinational
repair of double-stranded DNA breaks. Mutations in the lower
eukaryotic homologues of RAD51 result in a deficiency in the
repair of double-stranded DNA breaks. Loss of RAD51 function
would therefore be expected to result in an elevated mutation
rate, leading to accumulation of DNA damage and, hence, to
increased cancer risk. RAD51 interacts directly or indirectly with
a number of proteins implicated in breast cancer, such as
BRCA1 and BRCA2. Similar to BRCA1 mice, RAD51-/- mice
are embryonic lethal. The RAD51 gene region has been shown
to exhibit loss of heterozygosity in breast tumours, and
deregulated RAD51 expression in breast cancer patients has
also been reported. Few studies have investigated the role of
coding region variation in the RAD51 gene in familial breast
cancer, with only one coding region variant – exon 6 c.449G>A
(p.R150Q) – reported to date.
Methods All nine coding exons of the RAD51  gene were
analysed for variation in 46 well-characterised, BRCA1/2-
negative breast cancer families using denaturing high-
performance liquid chromatography. Genotyping of the exon 6
p.R150Q variant was performed in an additional 66 families.
Additionally, lymphoblastoid cell lines from breast cancer
patients were subjected to single nucleotide primer extension
analysis to assess RAD51 expression.
Results No coding region variation was found, and all intronic
variation detected was either found in unaffected controls or
was unlikely to have functional consequences. Single nucleotide
primer extension analysis did not reveal any allele-specific
changes in RAD51 expression in all lymphoblastoid cell lines
tested.
Conclusion Our study indicates that RAD51  is not a major
familial breast cancer predisposition gene.
Introduction
Hereditary breast cancer accounts for around 5–10% of all
breast cancer cases, while the other 90–95% is assumed to
be 'sporadic', with no apparent family history. A large propor-
tion of familial breast cancer (<40%) can be attributed to
mutations in the high-risk genes BRCA1  and BRCA2  [1].
Additional breast cancer genes have been discovered, largely
through disease syndromes displaying a predisposition for
breast cancer. Breast cancer in families with syndromes such
as Li-Fraumeni syndrome (resulting from p53 gene mutations)
[2] and Cowden syndrome (the mutated PTEN  gene) [3],
however, are each estimated to account for less than 1% of
hereditary breast cancer, and mutations in ATM  (the gene
mutated in ataxia telangiectasia) and CHEK2 are also pre-
dicted to account for only a small proportion of familial breast
cancer [4,5]. The genetic basis of the large majority of familial
breast cancer therefore remains unaccounted for.
It is well known that deficiencies in DNA repair can lead to car-
cinogenesis. Double-stranded DNA breaks (DSBs) may be
the most detrimental form of DNA damage because, if left
unrepaired, the detection of broken chromosomes will lead to
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cell death. Additionally, if DSBs are repaired improperly, they
can result in chromosomal translocations and cancer [6]. Cen-
tral to the repair of DSBs by homologous recombination is
RAD51, a homologue of the Escherichia coli DNA repair pro-
tein, RecA. RAD51 functions in DNA repair by mediating
homologous pairing and strand exchange reactions [7], and its
importance is further supported by the presence of many
highly conserved orthologues [8].
RAD51 interacts (directly or indirectly) with a large number of
proteins involved in DNA repair and the cell cycle, among oth-
ers, as reviewed by Richardson [9]. Interestingly, four of these
proteins – BRCA1, BRCA2, p53 and ATM – have been shown
to be breast cancer predisposition genes in high-risk families.
Additionally,  RAD51-/- mice are embryonic lethal, similar to
BRCA1-/- mice [10]. Alteration in either the expression or pro-
tein structure of RAD51 could therefore have similar deleteri-
ous effects on these essential pathways, leading to breast
cancer.
Besides the interactions of RAD51 with key players in breast
tumourigenesis, there is additional evidence to support a role
for RAD51 in breast cancer. The RAD51 gene is located at
chromosome position 15q15.1 [11], a region shown to exhibit
loss of heterozygosity in a large range of cancers, including
those of the lung, the colorectum and the breast [12]. Specif-
ically, 70% of breast tumours (from subjects with an unknown
family history) [12] and 32% of sporadic (nonfamilial) breast
cancers have been found to exhibit loss of heterozygosity of
this region [13]. RAD51 expression has also been found
altered in both primary tumours and cancer cell lines. RAD51
mRNA expression in 16/16 of tumours from BRCA1/2 muta-
tion-negative familial breast cancer patients was found to be
one-half of that of the BT-474 breast cancer cell line [14], and
protein levels were found to be decreased in 30% of breast
tumours from a combination of sporadic and high-risk breast
cancer patients [15].
In contrast, there are reports of increased RAD51 expression
in tumours and cancer cell lines. Ma and colleagues [16]
detected an increase in RAD51 mRNA expression in Ductal
Carcinoma In Situ-Invasive Ductal Carcinoma transition and
high-tumour-grade breast cancers, while it has also been
found that overexpression of RAD51 correlates with histologi-
cal grading of Invasive Ductal Carcinoma [17]. There are
numerous reports of RAD51 overexpression in a large range
of cancer cell lines, including cervical cancer, prostate cancer
and breast cancer [18].
These RAD51 expression data are difficult to reconcile with a
suppressor function, as suggested by the loss of heterozygos-
ity data and knockout mouse data. Instead, the data suggest
that any dysregulation of RAD51 may be associated with
downstream biological and clinical effects. Indeed, it has been
demonstrated that homologous pairing and strand transfer,
essential events in the repair of DSBs, require stoichiometric
amounts of RAD51 such that overexpression or underexpres-
sion of RAD51 results in a lack of formation of structures fun-
damental in the DSB repair process [19].
Despite the presented evidence for a role for deregulated
expression of RAD51 in DSB repair defects and/or breast
cancer, there have been few studies assessing the effects of
RAD51  gene variation on breast cancer risk. These have
largely focused on assessing the risk associated with a poly-
morphic variation in RAD51. Although there is some evidence
that the rare -135G>C variant in RAD51 is involved in modify-
ing the BRCA1/2-mutation-positive breast cancer phenotype,
studies focusing on the association between the RAD51 -
135G>C and -172G>T variants and breast cancer risk using
case-control analysis have shown little support for a significant
association with breast cancer [20].
With regard to RAD51 mutations and cancer predisposition,
three studies have used various mutation detection methodol-
ogies to screen RAD51 in breast cancer patients. An analysis
of 93 early-onset breast cancer cases, 9% of which had a
strong family history, revealed no coding region variation [21].
A second study in 2000 assessed a Japanese population of
45 well-characterised high-risk breast cancer patients using
single-strand conformation polymorphism (SSCP) analysis
and detected one relatively rare variant, an arginine for
glutamine substitution at amino acid 150 (c.449G>A) [22].
No other sequence alterations were detected in the Japanese
study. Rapakko and colleagues [23] recently used conforma-
tion-sensitive gel electrophoresis to investigate 74 high-risk
and 52 moderate-risk breast and/or ovarian cancer families of
Finnish descent. All of the variation detected was noncoding
and a majority was found in both cases and controls. It has
been reported, however, that the sequence variation detection
sensitivity of conformation-sensitive gel electrophoresis and
SSCP is around 75% and 60–85%, respectively [24,25], and
it is possible that some variation was not detected. We there-
fore sought to determine whether there is a role for variation in
the entire RAD51  coding region (and surrounding intronic
regions) in index cases from a well-characterised set of 49
BRCA1/2 mutation-negative breast cancer families, using the
highly sensitive technique denaturing high-performance liquid
chromatography (DHPLC). These families included a subset
of families where cancer-affected individuals were shown to
share a haplotype around the RAD51  locus. We also
screened index cases from 71 families specifically for the pre-
viously reported RAD51 p.Arg150Gln variant [22].
Methods
Participants
Multiple-case breast cancer families were ascertained through
the Kathleen Cuningham Foundation Consortium for Research
into Familial Breast Cancer [26]. Ethics approvals were
obtained from the Ethics Committees of the Peter MacCallumAvailable online http://breast-cancer-research.com/content/8/3/R26
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Cancer Institute and the Queensland Institute of Medical
Research, and all participants gave written informed consent.
Inclusion criteria for this study included the following seven sit-
uations: criterion 1, the family contained four or more cases of
breast cancer or contained at least three breast cancer cases,
one of which possessed 'high-risk' features such as age at
onset <40 years of age, the presence of male breast cancer in
the family, bilateral breast cancer or ovarian and breast cancer
in the same subject; criterion 2, at least two of the breast can-
cer cases in the family were alive, along with four or more liv-
ing, unaffected, female first-degree or second-degree relatives
over 18 years of age; criterion 3, three or more blood samples
from breast cancer cases (on the same side of the family) were
available; criterion 4, no pathogenic mutation in BRCA1 or
BRCA2 had been identified in the family; criterion 5, no vari-
ants of unknown pathogenic significance in BRCA1  or
BRCA2 had been identified in the family; criterion 6, a total of
11 or more blood samples from the family were available for
genotyping analysis; and criterion 7, where data were available
for a limited number of families, RAD51  haplotype sharing
analysis (D15S1012, D15S994 and D15S978 located within
2 Mb of RAD51) showed evidence of a haplotype shared by
affected participants in the RAD51-containing region,
15q15.1.
Fifty per cent of index cases (the youngest available breast
cancer case) had been tested by diagnostic laboratories for
mutations in BRCA1 and BRCA2 by full sequencing. There
were no differences in allele frequency for any RAD51 variant
when cases screened for BRCA1/2 mutation were compared
with the total breast cancer sample.
A total of 73 index cases from 71 families fitting the first four
criteria were genotyped for the RAD51  exon 6 c.449G>A
(p.Arg150Gln) variant. A total of 51 index cases from 46 fam-
ilies fitting all seven criteria were screened for variation across
the entire RAD51 coding region. A small overlap of five indi-
viduals from five families was analysed using both approaches.
Multiple index cases were screened from a given family when
it contained two cases with the same age at onset of breast
cancer. For families screened across the entire RAD51 coding
region, four families also contained individuals with either tes-
ticular or ovarian cancers and, if available, these subjects were
also screened for variation in RAD51 due to the high expres-
sion of RAD51 in these tissues [22].
A control population of one of each pair of 93 unrelated,
female, monozygotic twins (from a sample of 3,348 twin pairs
described previously) was analysed to determine the control
frequency of any variation detected in the RAD51 gene in this
study. Individuals were almost exclusively of European origin
and had been recruited through the Australian Twin Registry
[27].
RAD51 variation analysis
The RAD51 c.449G>A (p.Arg150Gln) variant was screened
using PCR and restriction fragment length polymorphism anal-
ysis. Forward primer AAGATGTCATGAGGAGCTTGG and
reverse primer GCCATAGTCTCTCTTATCTAAACCAG
spanned the MspI site present in the wildtype sequence (and
Table 1
RAD51 PCR conditions
Exon PCR fragment Forward primer Reverse primer Annealing 
temperature (°C)a
Size (bp) DHPLC 
temperature (°C)
1 1 GCAAGCGAGTAGAGAAGTGGA AACTGCCGCTGAGCACTG 54 218 65
2 2 ATGGCCTTGGCTTTTCCTAA GGCCCTGCCAGACATATTTA 54 391 57
3 3 TGGAACCAACTTCCCATCTC TTCCCACTAATGCCTCCCTA 54 341 58
4 4 CTCTTCCCATTGCACACCTT CACCTGGCCTTCCTCTATCTC 54 371 52, 57
5 5 TCTGATGAGCTCCAAGAACA TGACATGGAAGGATTTTGAAG 51 344 58
6 6 AAGGGAATGCCTCCTTCCTA CCAAACTAACCCTGGCAATC 54 314 59
7 7 CAAATTGCTCATCTGCCTG TGAGGCACCGTTTAACAAGA 54 397 59
8 8 TGGTAAGGAAGGGACCAGAA TGTGGCCATAGACACTCCAA 57 390 60
9 9 TCGTTATTTTGTGGGGGAAA ACAGGGGAGAGGCATATCAA 54 447 58
10 10a TTGGTGCTTTGGTCTGTGTC ATACCCCTCCTCCAAAACCA 54 409 59
10 10b CAGGAGACAGGTCAGTAGTCACA AGGTTTGGCACAAGACTCCA 51 374 57
10 10c TGATCTTGTGTAAGGGTTTGGTT GCAATCTCGACTCACTGCAA 51 375 60
10 10d GATAGCCTGAGGTGGGAGAA TCTGCAAGTGGGACTTTCCT 54 319 60
a'Touchdown' PCR amplification conditions were as follows: denaturation at 94°C for 10 minutes, followed by two cycles of 94°C for 30 seconds, 
30 seconds at the fragment annealing temperature (TA) + 6°, and 72°C for 30 seconds. The conditions remained the same for the rest of the PCR 
except for the annealing temperature, which consisted of two cycles at (TA + 4°C), then two cycles at (TA + 2°C) and, finally, 35 cycles at the TA. A 
final extension step was conducted at 72°C for 7 minutes.Breast Cancer Research    Vol 8 No 3    Lose et al.
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lost in the A allele). PCR reactions were carried out in a 20 µl
mixture containing 15 ng genomic DNA, 800 nM each primer,
200 µM each dATP, dCTP, dGTP and dTTP (Promega, Madi-
son, WI, USA), 1.5 mM MgCl2, 1 × PCR buffer and 1 U Ampl-
iTaq Gold polymerase (PE Applied Biosystems, Foster City,
CA, USA). PCR amplification conditions were 5 minutes initial
denaturation at 94°C, 30 cycles of 20 seconds at 94°C/20 s
at 55°C/20 s at 72°C, and 10 minutes final extension at 72°C.
MspI (NEB, Ipswich, MA, USA) digestion (as specified by the
manufacturer) of the 205 bp PCR product yielded fragments
of 89 bp and 116 bp for the wildtype G allele, with a single
fragment of 205 bp for the A allele. Digested PCR products
were separated on a 4% Nusieve agarose gel.
Primers encompassing the 10 exons of RAD51  (and sur-
rounding intronic regions) (Hs.446554; Unigene, NCBI) were
designed using Primer3 software [28] (Table 1). PCR reac-
tions were carried out in a 20 µl mixture containing, at final vol-
ume, 15 ng genomic DNA, 20–40 pmol each primer, 200 µM
each dATP, dCTP, dGTP and dTTP (Promega), 1.5–2 mM
MgCl2, 1 × PCR buffer and 1 U AmpliTaq Gold polymerase
(PE Applied Biosystems). For some fragments, 0.5–1 M
betaine was utilised to improve PCR and/or DHPLC profiles.
The 'touchdown' PCR amplification conditions are detailed in
Table 1. All products (and H2O controls) were first visualised
on a 1.5% agarose gel before denaturation by heating to 95°C
for 5 minutes and cooling to 60°C over a period of 30 minutes.
Samples were analysed on a Varian Helix DHPLC system (Var-
ian, Palo Alto, CA, USA) at the recommended melt tempera-
ture(s) as determined by the Stanford DHPLC Melt Program
[29] (detailed in Table 1). Analysis of the results was carried
out using Star Workstation Reviewer software (version 5; Var-
ian) and any aberrant or shifted profiles were reamplified for
repeat by DHPLC before being sequenced using the Big-Dye
version 3.1 sequencing chemistry and PE Applied Biosystems
377 sequencer.
Allelic expression analysis (single nucleotide primer 
extension)
Lymphoblastoid cell lines (LCLs) were derived from individuals
previously assessed for RAD51 variation and found to pos-
sess common single nucleotide polymorphisms (SNPs). All
lines were grown in RPMI 1640 media with 10% foetal calf
serum and 1% penicillin/streptomycin. RNA was extracted
from LCLs using TriReagent (Sigma Chemicals, Perth, WA,
Australia) according to the manufacturer's instructions. The
RNA quality was checked by northern gel analysis and 1 µg
each sample was placed in a reverse transcription-PCR
reaction using Superscript III RNAse H-  Reverse Tran-
scriptase, according to the manufacturer's instructions (Invit-
rogen, Carlsbad, CA, USA). PCR was then performed using
the RAD51  exon 10c primers (Table 1), and the resulting
product was purified using a Qiagen PCR purification kit (Qia-
gen, Hilden, Germany).
Table 2
Variation in the RAD51 gene
Gene region PCR fragment Nucleotide change Amino acid change Number (%) of 
heterozygous familiesa
Number (%) of 
heterozygous controls
Exon 1 (5' UTR) 1 c.-135G>C - 3/28 (10.7%) N/D
Exon 1 (5' UTR) 1 c.-172G>T - 16/33 (48.5%) N/D
Intron 2 2 c.97+110A>G - 3/46 (6.5%) 16/93 (17.2%)
Intron 3 4 c.226-33T>G - 11/46 (23.9%) 23/93 (24.7%)
Intron 3 4 c.226-70T>A - 20/46 (43.5%) 43/93 (46.2%)
Intron 3 4 c.226-72delA - 2/46 (4.3%) 8/93 (8.6%)
Intron 3 4 c.226-33T>G and c.226-70T>A - 4/46 (8.7%) 8/93 (8.6%)
Intron 3 4 c.226-33T>G and c.226-72delA - 1/46 (2.1%) 0/93 (0%)
Intron 3 4 c.226-70T>A and c.226-72delA - 1/46 (2.1%) 6/93 (6.5%)
Intron 4 5 c.344-36T>G - 3/46 (6.5%) 16/93 (17.2%)
Exon 6 6 c.449G>A p.R150Qb 0/46 (0%), 0/66 (0%) N/D
Intron 7 7 c.644+57G>T - 1/46 (2.2%) 0/93 (0%)
Intron 8 9 c.775-41G>C - 1/46 (2.2%) N/D
Exon 10 (3' UTR) 10b c.1020*+502T>G - 19/46 (41.3%) N/D
Exon 10 (3' UTR) 10c c.1020*+718G>A - 18/44 (40.9%) N/D
Exon 10 (3' UTR) 10d c.1020*+927T>C - 17/42 (40.4%) N/D
UTR, untranslated region; N/D, not determined aValues expressed as the number of heterozygous families because all related individuals shared 
the same genotype. bReported in Kato and colleagues [22].Available online http://breast-cancer-research.com/content/8/3/R26
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Primers located directly adjacent to the exon 10
c.1020*+718G>A SNP (forward primer, TTAAGTC-
CAGCTTGGCCAAG; and reverse primer, TGTAGAGAT-
GGGATTTCACCA) were then used in single-cycle PCR
reactions incorporating radiolabelled dNTPs. Both forward
and reverse reactions were performed to verify results. Radi-
olabelled fragments were separated on a 10% denaturing acr-
ylamide gel, and were visualised by autoradiography [30].
Densitometric analysis was performed using Fujifilm Multi-
gauge 2003 software (Fuji Photo Film Co., Tokyo, Japan).
Results
The c.449G>A (p.Arg150Gln) variant was not detected in any
of the 71 families genotyped directly for this variant, nor was it
detected by DHPLC screening across this region in an addi-
tional 41 families.
DHPLC analysis of 51 index breast cancer cases from 46 fam-
ilies with a strong family history revealed 13 different sequence
variations, all of which were located in noncoding regions
(Table 2).
The intron 7 and intron 8 variants have not been previously
described. The intron 7 c.644+57G>T variant was not found
in control subjects. This variant is not thought to be patho-
genic, however, because, although the G nucleotide is con-
served in the chimpanzee, the mouse and the rat [31], the
variant is deeply intronic and is not predicted to alter splicing
using the SpliceSiteFinder prediction program [32]. The intron
8 (c.775-41G>C) variant was not tested for in controls, but it
is also unlikely to be functional due to its deep intronic location
and the lack of predicted splicing effects.
All of the remaining five variants occurred at greater frequency
in controls than cases. The intron 2 (c.97+110A>G) and
intron 4 (c.344-36T>G) variants appeared to occur on the
same haplotype in all cases and controls. Variants detected in
the 5' untranslated region and the 3' untranslated region were
common SNPs that have been reported previously, and were
found in this population at the expected frequencies.
To assess the possibility that allelic imbalance of RAD51
expression may occur in breast cancer patients, we chose a
common exonic SNP – exon 10 c.1020*+718G>A – as a
marker of RAD51  gene expression, and we assessed four
LCLs from individuals heterozygous for these variants using
single nucleotide primer extension. The experiment was per-
formed in both forward and reverse directions and was con-
ducted twice, allowing verification of results. In all LCLs tested
there was no evidence of one allele being favourably
expressed over the other allele (data not shown).
Discussion
RAD51 plays a central and critical role in the DNA repair proc-
ess and also interacts with a number of proteins involved in
important pathways, such as cell-cycle regulation and DNA
damage signalling. Four studies have investigated the coding
region of RAD51 for variation in breast cancer to date. Bell
and colleagues [21] screened 93 early-onset (<40 years)
breast cancer cases, 9% of which had a strong family history,
for mutations in RAD51. A yeast-based protein truncation
assay revealed no truncating mutations, and sequencing of a
subset of 27 individuals with age at onset <30 years revealed
no coding region variation. In the same study, a protein trunca-
tion assay of 15 breast cancer cell lines also revealed no trun-
cating mutations.
Schmutte and colleagues [33] screened the RAD51 coding
region and the surrounding intron/exon boundaries in 41
breast carcinomas (family history unknown) by SSCP but
found no mutations.
There has been one report of a missense variant in RAD51
being detected in a breast cancer population to date. In a Jap-
anese population of 20 breast cancer cases with a strong fam-
ily history and 25 individuals with other high-risk factors such
as bilateral breast cancer, and so on, a G>A nucleotide sub-
stitution was detected by SSCP in two individuals with bilat-
eral breast cancer, which results in an arginine residue being
substituted for a glutamine residue at amino acid position 150
of RAD51 [22]. This was an interesting finding as glutamine
and arginine possess quite different physical properties that
could be predicted to affect the RAD51 protein. No other cod-
ing region variation was detected, but the sensitivity of SSCP
to detect variation is reported as only 60–85% [25].
In the present study we failed to detect the RAD51 c.449G>A
(p.R150Q) variant in a large, well-characterised Australian
familial breast cancer sample set. Our study assessed 112
high-risk breast cancer families for this variant, with our inclu-
sion criteria (see Methods, first inclusion criterion) being simi-
lar to those of Kato and colleagues [22] aside from the fact
that the BRCA1/2 mutation status was not reported in the Jap-
anese study. The p.R150Q variant has not been reported in
the National Center for Biotechnology Information (NCBI)
SNP database [34] but it appears that it may be a relatively
rare population-specific variant, and is probably not relevant to
breast cancer in the Australian population.
Rappako and colleagues [23] recently used conformation-
sensitive gel electrophoresis to screen 74 high-risk and 52
moderate-risk Finnish breast and/or ovarian cancer families for
variation in the RAD51 gene. The inclusion criteria for a 'high-
risk' family was similar to the current study, but we specifically
investigated breast cancer patients and several families that
shared a haplotype in the RAD51 region. In addition, DHPLC
has been reported to be a more sensitive technique for detect-
ing sequence variation [24]. Similar to the current study, no
coding region variation was detected.Breast Cancer Research    Vol 8 No 3    Lose et al.
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We did not detect any coding region variation in the RAD51
gene using the highly sensitive mutation detection technique
DHPLC. A number of intronic variants were found. All variants,
however, were either present at a similar frequency in controls
and/or were located deep in the intron, and were therefore
predicted not to have any functional effects. Additionally, sin-
gle nucleotide primer extension analysis did not reveal any
change in expression of RAD51 in LCLs from breast cancer
patients, indicating that there is little, if any, allelic effect on
RAD51  expression due to known or undetected genetic
variation.
Conclusion
The aim of the present study was to attempt to elucidate a role
for RAD51 as a high-risk breast cancer predisposition gene
using DHPLC and well-characterised non-BRCA1/2 familial
breast cancer patients. We did not detect any variation in the
coding region of RAD51, which may further imply the impor-
tance of maintaining the structural integrity of such a vital com-
ponent of the DNA repair pathway. Although other noncoding
variation in the RAD51 gene may be involved in BRCA1/2-
mutation-negative breast cancers, the absence of coding or
untranslated region mutations in this set of well-characterised
familial cases implies that RAD51 is not a major familial breast
cancer predisposition gene.
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